Tiny Corbus posts midstage win–just–with resunab in systemic sclerosis
The little-known small cap Corbus Pharmaceuticals ($CRBP), last year touted as a rival to Vertex ($VRTX), has published positive top-line results from its experimental med resunab in patients with a disease that can cause major fibrosis throughout the body. Read more >>